Imlygic (Talimogene Laherparepvec)

Talimogene laherparepvec is a genetically engineered herpes simplex virus that replicates selectively within cancer cells. As the virus lyses the tumor cells, it releases GM‑CSF, a protein that attracts and activates immune cells, thereby enhancing the body’s own anti‑tumor immunity.

The dosing regimen for Imlygic is individualized by the treating oncologist based on tumor characteristics and patient factors. The prescriber determines the volume and frequency of intralesional injections according to the approved label and clinical guidelines.

Safety of Imlygic in pregnancy and lactation has not been established. Because it contains a live, genetically modified virus, it is generally avoided in pregnant or nursing women unless the potential benefit outweighs the potential risk, as decided by the physician.

To request Imlygic, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics), and necessary import documentation.

Imlygic differs from conventional systemic therapies such as checkpoint inhibitors or targeted kinase inhibitors because it is delivered directly into tumor lesions and uses an oncolytic virus to trigger local and systemic immunity. It is often considered when surgery is not possible and can be combined with other immunotherapies for synergistic effect.

Imlygic must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging, protected from light, and must never be frozen or shaken. Prior to administration, the solution should be inspected for particulate matter and used within the time frame specified by the manufacturer.

Imlygic is given as an intralesional injection directly into measurable melanoma lesions. The injection is performed by a qualified healthcare professional under aseptic conditions, typically in a clinical setting, and the volume injected is based on lesion size and treatment protocol.

Serious risks include cellulitis or other severe infections at the injection site, herpetic keratitis affecting the eye, disseminated viral infection especially in immunocompromised patients, and rare severe allergic reactions such as anaphylaxis. Patients should be monitored closely for these events.

Imlygic is contraindicated in patients with active systemic infections, those receiving systemic immunosuppressive therapy, individuals with known hypersensitivity to any component of the product, and patients who have received live attenuated vaccines within four weeks prior to treatment.